Clinical evaluation of a trabecular microbypass stent with phacoemulsification in patients with open-angle glaucoma and cataract

Overview of attention for article published in Clinical Ophthalmology, September 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#36 of 3,757)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 12 news outlets

twitter: 3 X users

Citations

dimensions_citation: 53 Dimensions

Readers on

mendeley: 43 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 14 news stories from 12 outlets.

Glaukos Technologies Featured in Various Presentations at 2016 American Academy of Ophthalmology Conference

Business Wire, 06 Oct 2016

SAN CLEMENTE, Calif.--( BUSINESS WIRE )-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions...

Fresh News, 27 Sep 2016

Study in Clinical Ophthalmology Reveals Mean IOP of 15.17 mm Hg and 56% Reduction in Mean Glaucoma Medications 2 Years…

New Study Underscores Ability of iStent Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

ABC 7 News KSWO, 27 Sep 2016

Study in Clinical Ophthalmology Reveals Mean IOP of 15.17 mm Hg and 56% Reduction in Mean Glaucoma Medications 2 Years…

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions …

Yahoo! Finance USA, 27 Sep 2016

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on the…

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery - Press Release

Digital Journal, 27 Sep 2016

SAN CLEMENTE, Calif.--(Business Wire)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Yahoo! Finance UK , 27 Sep 2016

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on the…

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Minyanville: Finance , 27 Sep 2016

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of…

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Business Wire, 27 Sep 2016

SAN CLEMENTE, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Yahoo! Finance Singapore, 27 Sep 2016

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on the…

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Stock Nod: Quotes, 27 Sep 2016

(NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough…

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained ...

BioMed Reports, 27 Sep 2016

Sept. 27, 2016 11:00 UTC SAN CLEMENTE, Calif.--( BUSINESS WIRE )-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical…

Glaukos Release New Study Underscores Ability Of Istent Trabecular Micro Bypass Stent To Achieve Sustained Reductions In IOP And Medication Use In

Device Space, 27 Sep 2016

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…

Glaukos Release: New Study Underscores Ability Of Istent Trabecular Micro-Bypass Stent To Achieve Sustained Reductions In IOP And Medication Use In Glaucoma Patients Undergoing Cataract Surgery

Biospace, 27 Sep 2016

SAN CLEMENTE, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…

International Study Shows Favorable 3-Year Results of 2 Glaukos iStent® Trabecular Micro-Bypass Stents as Initial Treatment for Naïve Glaucoma

Stock Nod: Quotes, 22 Sep 2016

(NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough…

Dove Medical Press

Article Metrics

Clinical evaluation of a trabecular microbypass stent with phacoemulsification in patients with open-angle glaucoma and cataract

About this Attention Score

Mentioned by

Citations

Readers on

Glaukos Technologies Featured in Various Presentations at 2016 American Academy of Ophthalmology Conference

Business Wire, 06 Oct 2016

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions...

Fresh News, 27 Sep 2016

New Study Underscores Ability of iStent Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

ABC 7 News KSWO, 27 Sep 2016

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions …

Yahoo! Finance USA, 27 Sep 2016

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery - Press Release

Digital Journal, 27 Sep 2016

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Yahoo! Finance UK , 27 Sep 2016

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Minyanville: Finance , 27 Sep 2016

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Business Wire, 27 Sep 2016

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Yahoo! Finance Singapore, 27 Sep 2016

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery

Stock Nod: Quotes, 27 Sep 2016

New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained ...

BioMed Reports, 27 Sep 2016

Glaukos Release New Study Underscores Ability Of Istent Trabecular Micro Bypass Stent To Achieve Sustained Reductions In IOP And Medication Use In

Device Space, 27 Sep 2016

Glaukos Release: New Study Underscores Ability Of Istent Trabecular Micro-Bypass Stent To Achieve Sustained Reductions In IOP And Medication Use In Glaucoma Patients Undergoing Cataract Surgery

Biospace, 27 Sep 2016

International Study Shows Favorable 3-Year Results of 2 Glaukos iStent® Trabecular Micro-Bypass Stents as Initial Treatment for Naïve Glaucoma

Stock Nod: Quotes, 22 Sep 2016